Brought to you by 
Bayer licenses rights to Progenics' targeted prostate cancer antibody
28 Aug 2019
Executive Summary
Bayer AG received exclusive global development and commercialization rights to Progenics Pharmaceuticals Inc.'s Phase II antibodies that incorporate the latter's prostate cancer-specific membrane antigen (PSMA) technology.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer licenses rights to Progenics' targeted prostate cancer antibody
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice